In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Rani Therapeutics Holdings Inc (NASDAQ:RANI) experienced an 18% jump in its stock price following news that the ...

Sweetener consumption and genetic predisposition are independently associated with the risk for central precocious puberty (CPP), according to a study presented at ENDO 2025, the annual meeting of the ...

(HealthDay News) — From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx ...

Socially Isolated Older Adults are at 34% Higher Risk of Diabetes: ENDO 2025 StudyA study presented at ENDO 2025, the Endocrine Society’s annual meeting ...

ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Rhythm Pharmaceuticals announced three late-breaking abstracts accepted for presentation at ENDO 2025, highlighting new research on acquired hypothalamic obesity treatments.

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clin ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...